BOLDENONE UNDECYLENATE
Chemistry - An injectable anabolic steroid derived from testosterone, boldenone undecylenate hasa chemical name of 17 beta-hydroxyandrosta-1, 4-dien-3-one. The commercially available product isin a sesame oil vehicle. It may also be known by the name boldenone undecenoate or in the U.K. bythe trade name, Vebonol® (Ciba-Geigy).
Endogenous testosterone release may be suppressed by inhibiting lutenizing hormone (LH). Largedoses can impede spermatogenesis by negative feedback inhibition of FSH.
Anabolic steroids can also stimulate erythropoiesis. The mechanism for this effect may occur bystimulating erythropoeitic stimulating factor. Anabolics can cause nitrogen, sodium, potassium andphosphorus retention and decrease the urinary excretion of calcium.
Uses, Indications - Boldenone is labeled for use as adjunctive therapy "... as an aid for treatingdebilitated horses when an improvement in weight, haircoat, or general physical condition is desired" (Equipoise® package insert¯Solvay).
Contraindications/Precautions - The manufacturer (Solvay) recommends not using the drug onstallions or pregnant mares. Other clinicians state the that anabolic steroids should not be used ineither stallions or non-pregnant mares intended for reproduction. Boldenone should not be administered to horses intended for food purposes.
In humans, anabolic agents are also contraindicated in patients with hepatic dysfunction, hypercalcemia, patients with a history of myocardial infarction (can cause hypercholesterolemia), pituitaryinsufficiency, prostate carcinoma, in selected patients with breast carcinoma, benign prostatichypertrophy and during the nephrotic stage of nephritis.
The anabolic agents are category X (risk of use outweighs any possible benefit) agents for use inpregnancy and are contraindicated because of possible fetal masculinization.
Although not reported in horses, anabolic steroids have the potential to cause hepatic toxicity.
Overdosage - No information was located for this specific agent. In humans, sodium and waterretention can occur after overdosage of anabolic steroids. It is suggested to treat supportively andmonitor liver function should an inadvertent overdose be administered.
Diabetic patients receiving insulin, may need dosage adjustments if anabolic therapy is added ordiscontinued. Anabolics may decrease blood glucose and decrease insulin requirements.
Anabolics may enhance the edema that can be associated with ACTH or adrenal steroid therapy.
Drug/Laboratory Interactions - Concentrations of protein bound iodine (PBI) can be decreased in patients receiving androgen/anabolic therapy, but the clinical significance of this isprobably not important. Androgen/anabolic agents can decrease amounts of thyroxine-bindingglobulin and decrease total T4 concentrations and increase resin uptake of T3 and T4. Freethyroid hormones are unaltered and clinically, there is no evidence of dysfunction.
Both creatinine and creatine excretion can be decreased by anabolic steroids. Anabolic steroidscan increase the urinary excretion of 17-ketosteroids.
Androgenic/anabolic steroids may alter blood glucose levels. Androgenic/anabolic steroids maysuppress clotting factors II, V, VII, and X. Anabolic agents can affect liver function tests (BSP retention, SGOT, SGPT, bilirubin, and alkaline phosphatase).
Storage, Stability, Compatibility
Boldenone injection should be stored at room temperature;avoid freezing. Because it is in an oil vehicle, it should not be physically mixed with any other medications.Pharmacology - BOLDENONE UNDECYLENATE
In the presence of adequate protein and calories, anabolic steroids promote bodytissue building processes and can reverse catabolism. As these agents are either derived from or areclosely related to testosterone, the anabolics have varying degrees of androgenic effects.Endogenous testosterone release may be suppressed by inhibiting lutenizing hormone (LH). Largedoses can impede spermatogenesis by negative feedback inhibition of FSH.
Anabolic steroids can also stimulate erythropoiesis. The mechanism for this effect may occur bystimulating erythropoeitic stimulating factor. Anabolics can cause nitrogen, sodium, potassium andphosphorus retention and decrease the urinary excretion of calcium.
Uses, Indications - Boldenone is labeled for use as adjunctive therapy "... as an aid for treatingdebilitated horses when an improvement in weight, haircoat, or general physical condition is desired" (Equipoise® package insert¯Solvay).
Pharmacokinetics - BOLDENONE UNDECYLENATE
No specific information was located for this agent. It is considered to be along-acting anabolic, with effects persisting for up to 8 weeks. It is unknown if the anabolic agentscross into milk.Contraindications/Precautions - The manufacturer (Solvay) recommends not using the drug onstallions or pregnant mares. Other clinicians state the that anabolic steroids should not be used ineither stallions or non-pregnant mares intended for reproduction. Boldenone should not be administered to horses intended for food purposes.
In humans, anabolic agents are also contraindicated in patients with hepatic dysfunction, hypercalcemia, patients with a history of myocardial infarction (can cause hypercholesterolemia), pituitaryinsufficiency, prostate carcinoma, in selected patients with breast carcinoma, benign prostatichypertrophy and during the nephrotic stage of nephritis.
The anabolic agents are category X (risk of use outweighs any possible benefit) agents for use inpregnancy and are contraindicated because of possible fetal masculinization.
Adverse Effects, Warnings
In the manufacturer's (Equipoise®¯Solvay) package insert, onlyandrogenic (overaggressiveness) effects are listed. However, in work reported in both stallions andmares (Squires and McKinnon 1987), boldenone caused a detrimental effect in testis size, spermproduction and quality in stallions. In mares, the drug caused fewer total and large follicles, smallerovaries, increased clitoral size, shortened estrus duration, reduced pregnancy rates and severelyaltered sexual behavior.Although not reported in horses, anabolic steroids have the potential to cause hepatic toxicity.
Overdosage - No information was located for this specific agent. In humans, sodium and waterretention can occur after overdosage of anabolic steroids. It is suggested to treat supportively andmonitor liver function should an inadvertent overdose be administered.
Drug Interactions
No drug interactions were located for boldenone specifically. Anabolic agentsas a class may potentiate the effects of anticoagulants. Monitoring of PT's and dosageadjustment, if necessary, of the anticoagulant are recommended.Diabetic patients receiving insulin, may need dosage adjustments if anabolic therapy is added ordiscontinued. Anabolics may decrease blood glucose and decrease insulin requirements.
Anabolics may enhance the edema that can be associated with ACTH or adrenal steroid therapy.
Drug/Laboratory Interactions - Concentrations of protein bound iodine (PBI) can be decreased in patients receiving androgen/anabolic therapy, but the clinical significance of this isprobably not important. Androgen/anabolic agents can decrease amounts of thyroxine-bindingglobulin and decrease total T4 concentrations and increase resin uptake of T3 and T4. Freethyroid hormones are unaltered and clinically, there is no evidence of dysfunction.
Both creatinine and creatine excretion can be decreased by anabolic steroids. Anabolic steroidscan increase the urinary excretion of 17-ketosteroids.
Androgenic/anabolic steroids may alter blood glucose levels. Androgenic/anabolic steroids maysuppress clotting factors II, V, VII, and X. Anabolic agents can affect liver function tests (BSP retention, SGOT, SGPT, bilirubin, and alkaline phosphatase).